||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Eden Share Discussion Threads
Showing 2076 to 2097 of 2100 messages
I certainly would welcome an update on the statements made in the Half yearly report.
Sean Smith, Chief Executive Officer of Eden, said:
"So far this year, we have seen the first significant commercial sales of 3AEY into the agrochemicals market in Kenya, Greece, Italy and Spain. Whilst the botrytis season is not quite over and, as such, we don't have final sales quantities from our commercial partners for this season, Eden and its partners are very pleased with the sales that have been generated so far. Particularly in Italy where our partner, Sipcam Italia SpA, has invested a significant amount of resource into the commercial launch of "3logy", the brand name they have chosen for 3AEY in that region.
"For our nematicide product, negotiations are continuing with a multi-national industry leader, and progress has been made towards a satisfactory conclusion. A final agreement is expected this year covering multiple territories around the world, subject to further negotiations. A number of evaluation projects for both Eden's technologies and products are on-going and I am pleased with the progress that is generally being made, as well as with regulatory progress where territories such as the USA are now being actively pursued.
|SSThe board did a good job getting new money and larger instit shareholders on board, no doubt. Some take comfort from that but what about the bod themselves, £5k shares bought since May 15, its not a lot. I think shareholders are long overdue an update on the various apparent commercial progress in the form of Licencing JVs etc. the 1/2 year statement said very little. You must be getting nervous about the current state of the cash pile. Theres just so little to go on.|
It certainly would be good to hear more on sales..agree with you there.
It will be interesting to see how the Promotion from Sipcam and the publicity of Awards influenced sales.
Looks like we have more II buying recently (repeated £11.5k) which I see as positive.
I'm also looking forward to the French ticking some boxes and hearing about Eastman.|
|Super your post #1704. Surely you must have thought the company were having a laugh ? That tweet is pretty much their sales update to shareholders for the whole of 2016. PMSLQ12|
|Nice Find 33...
Good to See the Daily Mail covering Fraudulent Technology don't you think Frothy|
Hey Frothy one for you to watch since your so interested in Fraudulent technology.|
Discounter Lidl has launched a new range of own-label free-from and organic products in Italy, just-food.com has reported. The range will include more than 60 products including frozen, fresh and dried products, as well as wine and drinks.|
|Times they are a changing.
|Lots of Long term holders there.
I wonder what their price targets are, should various hurdles be achieved like good sales for 3aey, or a deal for our anti nematodes product.|
Ownership Eden Research PLC
Mutual Funds that own EDEN
% Shares Out
Change In Shares
% of Assets
As of Date
Artemis Alpha Trust Plc
Baronsmead VCT 2 Plc
Baronsmead VCT 3 Plc
Baronsmead VCT 5 Plc
|Selling fast in Italia
Institutions taking stakes
|Cimpany evangelosta bigo Miiky Wilteresta has pistedo simea bullishi mitteringsa recentlyo sheepleo. Nithinga new Winderu howe the $3m dillar Piwerhouse twripentechi ire douingo. piii|
Is that written in pronunciation style Scottish?|
|Company evangelist. MW has posted some bullish mutterings recently sheeple. Nothing new. Winder how the £3m dollar powerhouse twrpenetech are doing. Pmsl|
|Sipcam Getting the word around Italia
|worth checking out Eden's recent tweets
'Sipcam Italia’s “3logy” (aka Eden’s 3AEY botryticide)- nearly sold out at a major dealer near Bari, Italy last week'
'Eden’s 3AEY treated 300 hectares of table grapes at this producer near Bari'
It's good to hear, the recent results did say things had gone well in Italy.
Just a shame it's all so frustratingly slow, things like Portugal and France approving 3AEY are outside Eden's control, but this deal for the nematicide is taking aeons. I know the deal has to be right and that these multi-nationals don't excactly hurry themselves, all the same.....|
|You most likely right about the tough market environment.
I'm glass half full on the RNS/results. Time will tell.|
|Exactly SS a lot of words to explain away the fact the market for edens products is a tough environment and end users not as interested as BoD would have shareholders believe.|
The financial results for the period alone do not really highlight the progress the business has made in the first six months of FY2016F, in our view. We believe Eden has made some significant steps forward in H1 from an operational standpoint most particularly in terms of gaining the required regulatory approvals in a number of countries to enable the sales of its product 3AEY via in-country partners. Encouragingly, the period also saw the first commercial sales of 3AEY. Looking forward, we expect the second half of the year to see a continuation of the positive operational momentum reported in H1 that should also deliver more material financial benefits to the business. The heavy weighting of revenue to H2 is in part a reflection of the timing of the botrytis season in Southern Europe which typically begins in August and extends through harvest to mid to late September.
Products evaluation update
From a financial perspective, it is Eden’s’ products and technologies under commercial evaluation that are the key drivers behind our forecasts for FY2016F. In that respect, we note management’s comments that negotiations in regard to its nematicide product are continuing with a multi-national industry leader and progress has been made towards a satisfactory conclusion. A final agreement is expected this year covering multiple territories around the world subject to further negotiation.
Furthermore, a number of evaluation projects for both Eden’s technologies and products are ongoing and we note Sean Smith, CEO’s comments
“I am pleased with the progress that is generally being made as well as with regulatory progress where territories such as the USA are now being actively pursued”.
Value potential becoming increasingly visible
Overall, we believe H1 2016A has been a further period of progress for Eden with further regulatory approval and the company gaining its first commercial sales. Going forward, we expect further progress in H2 and we are hopeful that this can include some positive newsflow in relation to the group’s nematicide product. Such progress would not only be positive from a financial perspective but it would also add diversification to the group thereby further reducing its risk profile whilst adding to its commercial credibility.
With a strong balance sheet in place post the capital raising and ongoing tight cost control, the company looks well placed to accelerate its development over the coming years. Based on our assumptions Eden’s shares are trading on an EV/EBITDA ratio for FY2017F of 9.9x, which is projected to fall to a lowly 3.3x in the following year. This suggests a compelling opportunity, in our view. House Stock.|
|Pmsl £110,000 revenues in 6 months thats not even the MD's monthly wage.|